KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Globus Medical (GMED) Non Operating Income (2016 - 2025)

Globus Medical's Non Operating Income history spans 15 years, with the latest figure at $122.2 million for Q4 2025.

  • For Q4 2025, Non Operating Income rose 930.0% year-over-year to $122.2 million; the TTM value through Dec 2025 reached $236.5 million, up 4411.62%, while the annual FY2025 figure was $125.3 million, 5580.36% up from the prior year.
  • Non Operating Income reached $122.2 million in Q4 2025 per GMED's latest filing, up from $1.5 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $122.2 million in Q4 2025 to a low of -$19.5 million in Q4 2023.
  • Average Non Operating Income over 5 years is $13.2 million, with a median of $2.5 million recorded in 2021.
  • Peak YoY movement for Non Operating Income: crashed 343.96% in 2024, then soared 11140.12% in 2025.
  • A 5-year view of Non Operating Income shows it stood at $1.6 million in 2021, then surged by 396.81% to $8.1 million in 2022, then crashed by 341.32% to -$19.5 million in 2023, then surged by 160.8% to $11.9 million in 2024, then skyrocketed by 930.0% to $122.2 million in 2025.
  • Per Business Quant, the three most recent readings for GMED's Non Operating Income are $122.2 million (Q4 2025), $1.5 million (Q3 2025), and $112.1 million (Q2 2025).